Notizie aziendali
Questi comunicati stampa sono intesi come informazioni di riferimento per investitori e giornalisti statunitensi. Le informazioni contenute in ogni rassegna stampa sono aggiornate al momento della pubblicazione e KCI non si assume alcuna responsabilità per il loro aggiornamento in modo da riflettere gli sviluppi successivi.
KCI's LifeCell™ Corporation and Novadaq Technologies Enter North American Sales and Marketing Agreement for Exclusive Distribution of SPY® Imaging System
Prevena™ Incision Management System now available to all U.S. hospitals
New KCI Product Designed to Manage Incisions Following Surgery, Such as General, OB/GYN, Orthopedic, Cardiac Procedures
Prevena™ Incision Management System now available to all U.S. hospitals
KCI Obtains Favorable Ruling in German Patent Case
Court Finds Smith & Nephew's Renasys EZ Product Infringes KCI Patent; Issues Injunction
KCI Obtains Injunction against Smith & Nephew in United Kingdom
UK High Court of Justice Enters Injunction Against Smith & Nephew’s NPWT Products; Injunction Stayed Pending Expedited Appeal
KCI Boosts Research and Development Capabilities with Launch of Advanced Research and Technology Center
Innovation Center to Accelerate Company Mission of Making Healing Possible; New Organization Will Fuel Product Development and Commercialization
KCI Wins UK Patent Case Against Smith & Nephew
UK High Court of Justice Finds Smith & Nephew's Products Infringe Two NPWT Patents Exclusively Owned By KCI
KCI Prevena™ Incision Management System Licensed by Health Canada
Designed to Help Manage Patients' Incisions Successfully Following Surgery
KCI Receives FDA Clearance for Prevena™ Incision Management System
Postsurgical Incision Management Represents $1 Billion Global Market Opportunity: U.S. Approval Follows Prevena™ System Launch in Europe and Canada
KCI First Manufacturer to Commit to Submitting Product Labeling for FDA Medical Device Home Use Initiative
Move Signals KCI's Support of FDA's Goal of Ensuring Strong Standards for Patient Home Use
KCI Announces FDA Clearance of V.A.C.® Therapy for Venous Insufficiency Ulcers
Extends KCI's Reach Across All Three Major Chronic Wound Types